• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain

FDA to review four TNF drugs for cancer risk

Article

The Food and Drug Administration has begun a safety review of four tumor necrosis factor (TNF) inhibitors, after receiving over reports of cancer caused in children who were taking them.

The Food and Drug Administration has begun a safety review of four tumor necrosis factor (TNF) inhibitors, after receiving over reports of cancer caused in children who were taking them.

The four drugs are certolizumab (Cimzia), etanercept (Enbrel), adalimumab (Humira), and infliximab (Remicade). They treat a variety of immune system disorders, including Crohn's disease, plaque psoriasis, and juvenile idiopathic, rheumatoid, and psoriatic arthritis.

Lymphomas were half of the reported cancers: others included leukemia and melanoma.

All four drugs already carry warnings that they have been linked to cancers. There have been over 30 reports of children's cancers over the last decade. FDA is also requiring certolizumab manufacturer UCB Pharma to conduct a long-term risk study, which will take 10 years to complete.

Related Videos
Lawrence Eichenfield, MD
Lawrence Eichenfield, MD | Image credit: KOL provided
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx - stock.adobe.com.
Jonathan Miller, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.